A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

Summary

The purpose of this study is to evaluate the safety and clinical pharmacology of a single dose pharmacokinetics and pharmacodynamics of XOMA 358 in subjects with hypoglycemia associated with congenital hyperinsulinism.

Timeline

Start

2015-10

Primary completion

2017-01

Completion

2017-01

Drugs

Indications